Ritchlin, Christopher T <br/><br/>
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.  [electronic resource] 

 -  Lancet (London, England)  02 2020 
 - 427-440 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(19)33161-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Arthritis, Psoriatic--drug therapy<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Injections<br/>Interleukin-17--antagonists & inhibitors<br/>Male<br/>Middle Aged